Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

Cited In for PubMed (Select 19812437)

1.

The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding.

Mohr PG, Deng YM, McKimm-Breschkin JL.

Virol J. 2015 Apr 22;12(1):67. [Epub ahead of print]

2.

Antiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011.

Potdar VA, Dakhave MR, Kulkarni PB, Tikhe SA, Broor S, Gunashekaran P, Chawla-Sarkar M, Abraham A, Bishwas D, Patil KN, Kadam AA, Kode SS, Mishra AC, Chadha MS.

Indian J Med Res. 2014 Aug;140(2):244-51.

3.

Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.

Barrett S, McKimm-Breschkin JL.

Antiviral Res. 2014 Aug;108:30-5. doi: 10.1016/j.antiviral.2014.05.006. Epub 2014 May 20.

PMID:
24854981
4.

Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA.

Antimicrob Agents Chemother. 2014 May;58(5):2718-30. doi: 10.1128/AAC.02628-13. Epub 2014 Feb 24.

5.

Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.

Okomo-Adhiambo M, Nguyen HT, Abd Elal A, Sleeman K, Fry AM, Gubareva LV.

Influenza Other Respir Viruses. 2014 Mar;8(2):258-65. doi: 10.1111/irv.12215. Epub 2013 Dec 2.

6.

Comparative dynamics and distribution of influenza drug resistance acquisition to protein m2 and neuraminidase inhibitors.

Garcia V, Aris-Brosou S.

Mol Biol Evol. 2014 Feb;31(2):355-63. doi: 10.1093/molbev/mst204. Epub 2013 Nov 7.

7.

Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Burnham AJ, Baranovich T, Govorkova EA.

Antiviral Res. 2013 Nov;100(2):520-34. doi: 10.1016/j.antiviral.2013.08.023. Epub 2013 Sep 4. Review.

8.

Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic.

Hall RJ, Peacey M, Ralston JC, de Joux DJ, Bocacao J, Nicol M, Ziki M, Gunn W, Wang J, Huang QS.

Western Pac Surveill Response J. 2012 Oct 30;3(4):71-7. doi: 10.5365/WPSAR.2012.3.3.002. Print 2012 Oct.

9.

Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.

Yen HL, McKimm-Breschkin JL, Choy KT, Wong DD, Cheung PP, Zhou J, Ng IH, Zhu H, Webby RJ, Guan Y, Webster RG, Peiris JS.

MBio. 2013 Jul 16;4(4). pii: e00396-13. doi: 10.1128/mBio.00396-13.

11.

Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Wong DD, Choy KT, Chan RW, Sia SF, Chiu HP, Cheung PP, Chan MC, Peiris JS, Yen HL.

J Virol. 2012 Oct;86(19):10558-70. doi: 10.1128/JVI.00985-12. Epub 2012 Jul 18.

12.

Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV.

Viruses. 2010 Oct;2(10):2269-89. doi: 10.3390/v2102269. Epub 2010 Oct 13. Erratum in: Viruses. 2011 Aug;3(8):1415-6.

13.

Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards.

Järhult JD, Muradrasoli S, Wahlgren J, Söderström H, Orozovic G, Gunnarsson G, Bröjer C, Latorre-Margalef N, Fick J, Grabic R, Lennerstrand J, Waldenström J, Lundkvist A, Olsen B.

PLoS One. 2011;6(9):e24742. doi: 10.1371/journal.pone.0024742. Epub 2011 Sep 12.

14.

Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.

Barrett S, Mohr PG, Schmidt PM, McKimm-Breschkin JL.

PLoS One. 2011;6(8):e23627. doi: 10.1371/journal.pone.0023627. Epub 2011 Aug 17.

15.

Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques.

Kitano M, Itoh Y, Kodama M, Ishigaki H, Nakayama M, Ishida H, Baba K, Noda T, Sato K, Nihashi Y, Kanazu T, Yoshida R, Torii R, Sato A, Ogasawara K.

Antimicrob Agents Chemother. 2011 Nov;55(11):4961-70. doi: 10.1128/AAC.00412-11. Epub 2011 Aug 15.

16.

Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.

Richard M, Ferraris O, Erny A, Barthélémy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B.

Antimicrob Agents Chemother. 2011 Jun;55(6):2942-52. doi: 10.1128/AAC.01699-10. Epub 2011 Mar 21.

17.

Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.

Ujike M, Ejima M, Anraku A, Shimabukuro K, Obuchi M, Kishida N, Hong X, Takashita E, Fujisaki S, Yamashita K, Horikawa H, Kato Y, Oguchi A, Fujita N, Tashiro M, Odagiri T; Influenza Virus Surveillance Group of Japan.

Emerg Infect Dis. 2011 Mar;17(3):470-9. doi: 10.3201/eid1703.101188.

18.

Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.

Tamura D, Sugaya N, Ozawa M, Takano R, Ichikawa M, Yamazaki M, Kawakami C, Shimizu H, Uehara R, Kiso M, Kawakami E, Mitamura K, Kawaoka Y.

Clin Infect Dis. 2011 Feb 15;52(4):432-7. doi: 10.1093/cid/ciq183. Epub 2011 Jan 19.

19.

Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010.

Sheu TG, Fry AM, Garten RJ, Deyde VM, Shwe T, Bullion L, Peebles PJ, Li Y, Klimov AI, Gubareva LV.

J Infect Dis. 2011 Jan 1;203(1):13-7. doi: 10.1093/infdis/jiq005.

20.

Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.

Oakley AJ, Barrett S, Peat TS, Newman J, Streltsov VA, Waddington L, Saito T, Tashiro M, McKimm-Breschkin JL.

J Med Chem. 2010 Sep 9;53(17):6421-31. doi: 10.1021/jm100621s.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk